2019•Multiple Sclerosis JournalRequires access

Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: phase 3 PREVENT study

Jacqueline A. Palace, S J Pittock, Achim Berthele, Kazuo Fujihara, H J Kim, Miles J Levy, Ichiro Nakashima, Menderes Yusuf Terzi, Natalia A. Totolyan, S Viswanathan, Wang Kc, Andrea Pace, Marcus Yountz, R Armstrong, Dean M. Wingerchuk, Grp Prevents.

Open publisher page 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Neuromyelitis optica, Eculizumab, Spectrum disorder, Multiple sclerosis, Medicine, Aquaporin 4, Antibody, Immunology